---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-263406"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T20:51:16.006876+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte amends HQ lease to 258,581 RSF, subleases 16,731 SF to Iovance Biotherapeutics

## Summary
- Amended lease expands premises from ~113k to 258,581 RSF across floors 1-6, phased move-ins Feb 2025 through June 2026.
- Initial base rent $5.941-$6.026/RSF/month for existing premises; $6.00/RSF for additional; 8-month abatement, 3% annual escalations.
- Lease term 120 months from first additional premises commencement, with two 5-year renewal options.
- Subleased 16,731 RSF of Suite 100A to Iovance Biotherapeutics for 2 years at $5.95/RSF, rising to $6.1285/RSF after year one.
- Security deposit of ~$1.09M in letters of credit carried over from prior leases.

## SEC filing metadata
- accession: 0001193125-24-263406
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312524263406/0001193125-24-263406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312524263406/d847442d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-263406
- JSON: https://secwatch.observer/filing/0001193125-24-263406.json
- Plain text: https://secwatch.observer/filing/0001193125-24-263406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.